AbbVie Inc. and Roche are in line for a sales boost for their BCL-2 inhibitor, Venclexta/Venclyxto (venetoclax), after top-line data show success for the Phase III MURANO study of the small-molecule drug in combination with the anti-CD20 product rituximab (Roche's MabThera/Rituxan) in relapsed or refractory chronic lymphocytic leukaemia (CLL), a far larger population than its current label covers.
MURANO To Drive AbbVie/Roche's Venetoclax In CLL
Top-line MURANO data support Venclexta's current conditional approvals and expand its use into a broader population that should radically boost sales.
More from Clinical Trials
• By
The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.
• By
BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.
• By
While Henlius Biotech’s PD-L1-targeting antibody-drug conjugate HLX43 is struggling to catch up with Pfizer’s PF-08046054, the global frontrunner in the space, a key differentiation of the China-originated asset could lie in PD-L1-negative patients.
• By
BMS’s Phase III ODYSSEY-HCM study did not show statistical significance for either of its two primary endpoints.
More from R&D
• By
While Henlius Biotech’s PD-L1-targeting antibody-drug conjugate HLX43 is struggling to catch up with Pfizer’s PF-08046054, the global frontrunner in the space, a key differentiation of the China-originated asset could lie in PD-L1-negative patients.
• By
AstraZeneca logs growth in Japan despite a big reimbursement price cut for one of its top sellers and expects 40 approvals in the country over the next six years.
• By
BMS’s Phase III ODYSSEY-HCM study did not show statistical significance for either of its two primary endpoints.